E&G Advisors’s AstraZeneca AZN Stock Holding History

E&G Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$249K	Hold	1,541	–	–	0.05%	221
2026 Q2	$292K	Buy	1,541 +50	+3%	+$9.4K	0.06%	197
2026 Q1	$294K	Buy	1,491 +50	+3%	+$9.6K	0.07%	181
2025 Q4	$265K	Hold	1,441	–	–	0.06%	188
2025 Q3	$221K	Buy	+1,441	New	+$218K	0.05%	207
2025 Q2	–	Sell	-1,480	Closed	-$218K	–	211
2025 Q1	$218K	Buy	+1,480	New	+$214K	0.06%	192
2024 Q4	–	Sell	-1,505	Closed	-$235K	–	217
2024 Q3	$235K	Hold	1,505	–	–	0.06%	192
2024 Q2	$235K	Sell	1,505 -209	-12%	-$31.4K	0.07%	189
2024 Q1	$232K	Buy	+1,714	New	+$227K	0.07%	183

Other funds holding AZN

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

E&G Advisors's AZN Position: Q3 2026 in Review

E&G Advisors held its AstraZeneca (AZN) position steady in Q3 2026 at 1,541 shares worth $249K. The position accounts for 0.05% of the portfolio, ranked #221.

E&G Advisors first reported a position in AZN in Q1 2024 and has held it in 9 quarters since. The position peaked at $294K in Q1 2026. 1,062 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

E&G Advisors held 1,541 shares of AstraZeneca worth $249K as of Q3 2026.
E&G Advisors left its AstraZeneca share count unchanged in Q3 2026.
AstraZeneca made up 0.05% of E&G Advisors's portfolio in Q3 2026, its #221 holding.
E&G Advisors first reported a position in AstraZeneca in Q1 2024 and has held it in 9 quarters since.
E&G Advisors's AstraZeneca position peaked at $294K in Q1 2026.
1,062 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on E&G Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.